top of page
Executive Spotlights

Vedanta Biosciences Announces $106.5M Financing to Advance Pipeline of Bacterial Consortia Therapies

Cambridge, MA, April 25, 2023 (Business Wire) -- Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities. The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to microbiome therapy. Defined bacterial consortia are products of standardized composition manufactured from cell banks, bypassing the need to rely on donor fecal material of inconsistent composition.


Read full article here.

Recent Posts

See All

コメント


Life Science Headlines
bottom of page